|
VKTX | Viking Therapeutics, Inc. |
|
|
VKTX | Viking Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.12 |
| Leverage | 21.76% |
| Market Cap | $ 3.3B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -533.1m |
| Margin | -2119.81% |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.